Finoriq research workspace
AbCellera Biologics Inc. (ABCL) SEC Filings & Filing Highlights
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for. Review ABCL SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- Company
- AbCellera Biologics Inc. (ABCL)
- Ticker
- ABCL
- Market Cap
- $1.7B
- Latest Price
- $5.855
- Industry
- Biotech & Pharma
AbCellera Biologics Inc. (ABCL) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AbCellera Biologics Inc. (ABCL).
| Event | Form | Date |
|---|---|---|
| Appointment of Director On June 30, 2026, the Board of Directors (the "Board") of AbCellera Bio...Appointment of Director On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn S... | 8-K5.02 | 2026-07-06 |
| AbCellera Biologics Inc.: Corporate updateOn June 17, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing a preclinical research collaboration, option a... | 8-K8.01 | 2026-06-17 |
| AbCellera Biologics Inc.: Shareholder voteAbCellera Biologics Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2026. As of April 15, 2... | 8-K5.07 | 2026-06-12 |
| Appointment of Director On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biol...Appointment of Director On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor... | 8-K5.02 | 2026-06-05 |
| On May 11, 2026, AbCellera Biologics Inc., issued a press release announcing positive interim P...On May 11, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing positive interim Phase 1 data for ABCL635 from... | 8-K7.01 | 2026-05-11 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.